PACTR201301000445375已完成未知
se of Atorvastatin among HAART-treated adults with suboptimal immune recovery in Uganda
Damalie Nakanjako0 个研究点目标入组 30 人开始时间: 2012年10月26日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 90 Year(s)（—）
- 性别
- All
入选标准
- •Age 18years and above
- •HAART for at least 4 years
- •Sustained viral suppression
- •CD4 increase below 300 (from the baseline)
排除标准
- •History of opportunistic infection in the previous 6 months
研究者
相似试验
招募中
3 期
Effect of Atorvastatin in the management of COVID-19COVID-19.Coronavirus infection, unspecifiedB34.2IRCT20150221021159N7Esfahan University of Medical Sciences60
尚未招募
4 期
A clinical trial to compare the preventive effects of Atorvastatin and Rosuvasatin on kidney damage in patients undergoing cardiac surgeryCTRI/2023/08/056801Sreeja Nittoori
Unknown
3 期
Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence TrialHIV InfectionNCT03037372Makerere University320
已完成
不适用
Clinical study of atorvastatin on patients with hyperlipidemia. Comparison of the efficacy and safety between the original drug and its generic drugPatients with hyperlipidemia who have been treated with LipitorJPRN-UMIN000007302agano Kidney Evaluation Association (NKEA)100
招募中
不适用
Evaluation of the effect of Atorvastatin in diabetic type 2 patients in the morning and eveningIRCT20211211053359N1Babol University of Medical Sciences76